Brief: MBX Biosciences Announces Last Subject Last Visit In Phase 1 Trial
18/11/2024 13:12
Nov 18 (Reuters) - MBX Biosciences Inc MBX.O :
* MBX BIOSCIENCES ANNOUNCES LAST SUBJECT LAST VISIT IN PHASE
1
TRIAL OF MBX 1416 FOR THE TREATMENT OF POST-BARIATRIC
HYPOGLYCEMIA
* MBX BIOSCIENCES : LOOK FORWARD TO SHARING FULL-TOPLINE
RESULTS
OF MBX 1416 PROGRAM IN EARLY JANUARY 2025
Source text: ID:nGNX5yFt0s
Further company coverage: MBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MBX Biosciences
See all newsU.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
MBX Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: MBX Biosciences Announces Executive Leadership Transition To Support The Company’S Next Phase Of Growth
MBX Biosciences falls after executive shakeup
U.S. STOCKS ON THE MOVE-SpaceX, Tesla, Woodside Energy Group